Synonyms: example 37 [WO2020166680A1]
Compound class:
Synthetic organic
Comment: The chemical structure for emupertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. This is one of the EGFR inhibitor compounds claimed in Taiho Pharma patent WO2020166680A1 [1]. Analysis of Tiaho's decalred pipeline, suggests that emupertinib may be the INN for their candidate TAS3351 (intended for NSCL, but target not declared), as it can't be TAS6417 which has a different chemical structure and is assigned the INN zipalertinib. We await formal declaration of any name-to-structure association.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Yamamoto F, Mizutani T, Kasuga H, Fuchida Y, Hara S, Kobayakawa Y, Ogino E. (2020)
7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative. Patent number: WO2020166680A1. Assignee: Taiho Pharmaceutical Co., Ltd.. Priority date: 14/02/2020. Publication date: 20/08/2020. |